Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Pilot Study Of Alemtuzumab In Patients With Low Or INT-1 Risk Myelodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T-Cell Large Granular Lymphocytic Leukemia (T-LGL).

Next Previous
Search
Trial Profile

Phase II Pilot Study Of Alemtuzumab In Patients With Low Or INT-1 Risk Myelodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T-Cell Large Granular Lymphocytic Leukemia (T-LGL).

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Alemtuzumab (Primary)
  • Indications Aplastic anaemia; Large granular lymphocytic leukaemia; Myelodysplastic syndromes; T-cell prolymphocytic leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Dec 2013 Status changed from recruiting to discontinued as reported by M.D. Anderson Cancer Center.
    • 30 Sep 2013 Planned end date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
    • 22 Nov 2012 Planned number of patients changed from 29 to 32 as reported by M.D. Anderson Cancer Center.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top